Table 2.
Clinical and laboratory characteristics of patients with evidence of previous HCV infection
| Patient number | Sex | Age | Comorbidities | HCV-ab | HCV-RNA | Biologic therapies | Follow-up duration (weeks) | PASI baseline | PASI at last observation |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 50–54 | Hypertension, obesity | Positive | Undetectable | Ustekinumab | 220 | 30 | 5 |
| 2 | M | 50–54 | HBcAb+ | Positive | Undetectable | Risankizumab | 52 | 15 | 0 |
| 3 | M | 55–59 | Hypertension, CVD | Positive | Undetectable | Ixekizumab | 52 | 18 | 0 |
| 4 | M | 60–64 | PsA | Positive | Undetectable | Adalimumab, secukinumab, brodalumab | 104 | 10 | 1 |
HBV-ab antibody to HCV